Giovanni Abbadessa

Chief Medical Officer ModeX Therapeutics

Seminars

Thursday 11th September 2025
From Bispecifics to Tetraspecifics: Multiple Targets, One Drug
1:00 pm
  • Bi- vs Tri- vs Tetra-specific Antibodies
  • Tri-specifics can physiologically activate T cells and be well tolerated (eg HER2-CD3-CD28)
  • Tetra-specifics can tackle antigen heterogeneity and loss, while physiologically activating T cells
Giovanni Abbadessa